Home › Funds › Carlyle Group Inc. › PHAT
Carlyle Group Inc. position in PHAT
PHATHOM PHARMACEUTICALS INC · Health Care
Carlyle Group Inc. reported holding 3,496,808 shares of PHAT (PHATHOM PHARMACEUTICALS INC) in its Q3 2026 13F filing — a position valued at US$25.5M, representing 0.31% of its reported portfolio and ranking #3 among its reported holdings. Carlyle Group Inc. has disclosed PHAT holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How Carlyle Group Inc.'s PHAT position evolved
Carlyle Group Inc. first disclosed a stake in PHAT in Q3 2023 at 3,496,808 shares (US$36.2M). The position peaked in Q3 2024 at 3,496,808 shares, worth US$63.2M. Across 13 filings, Carlyle Group Inc. held the position steady without any share-count change. The most recent filing (Q3 2026) shows 3,496,808 shares valued at US$25.5M.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 3.50M | $36.19M | New |
| Q4 2023 | 3.50M | $31.93M | Hold |
| Q1 2024 | 3.50M | $37.10M | Hold |
| Q2 2024 | 3.50M | $35.84M | Hold |
| Q3 2024 | 3.50M | $63.19M | Hold |
| Q4 2024 | 3.50M | $28.39M | Hold |
| Q1 2025 | 3.50M | $21.92M | Hold |
| Q2 2025 | 3.50M | $33.53M | Hold |
| Q3 2025 | 3.50M | $41.05M | Hold |
| Q4 2025 | 3.50M | $57.98M | Hold |
| Q1 2026 | 3.50M | $38.85M | Hold |
| Q2 2026 | 3.50M | $37.94M | Hold |
| Q3 2026 | 3.50M | $25.53M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About PHAT and 13F data
PHAT (PHATHOM PHARMACEUTICALS INC) is a Health Care company. 29 other funds we track also report a position in PHAT — the largest reported positions include Frazier Life Sciences Management, L.P. (US$135.3M), Medicxi Ventures Management (Jersey) Ltd (US$54.5M), NEA Management Company, LLC (US$21.3M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding PHAT
- Frazier Life Sciences Management, L.P. 12.47M sh · $135.26M · Q2 2026
- Medicxi Ventures Management (Jersey) Ltd 7.46M sh · $54.49M · Q3 2026
- NEA Management Company, LLC 1.96M sh · $21.27M · Q2 2026
- 683 Capital Management, LLC 1.85M sh · $20.07M · Q2 2026
- Catalys Pacific, LLC 1.88M sh · $13.74M · Q3 2026
- Propel Bio Management, LLC 1.11M sh · $8.07M · Q3 2026
- EcoR1 Capital, LLC 625.00K sh · $6.78M · Q2 2026
More on Carlyle Group Inc.
FAQ
How long has Carlyle Group Inc. held PHAT?
Carlyle Group Inc. has disclosed PHAT holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
What is Carlyle Group Inc.'s current position in PHAT?
As of Q3 2026, Carlyle Group Inc. holds 3.50M shares of PHAT (PHATHOM PHARMACEUTICALS INC), valued at $25.53M, representing 0.31% of its reported portfolio and ranking #3.
Has Carlyle Group Inc. been buying or selling PHAT?
In the latest 13F filing (Q3 2026), Carlyle Group Inc. held unchanged its position in PHAT. The position peaked in Q3 2024 at 3.50M shares.
Which other funds hold PHAT?
Other major institutional holders of PHAT include Frazier Life Sciences Management, L.P., Medicxi Ventures Management (Jersey) Ltd, NEA Management Company, LLC, among 29 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.